Skip to page content

Startups to Watch: Mercury Bio ready to scale biomolecular drug delivery platform


Bruce McCormick
Bruce McCormick is the CEO of Mercury Bio, which emerged from stealth in August 2023.
Courtesy of Bruce McCormick

New Mexico Inno's 2024 Startups to Watch list highlights 10 startups we expect to capture headlines in the year ahead. The New Mexico Inno editorial team picked out the 10 companies through a nomination process and our own research and reporting.

You can read all about these 10 Startups to Watch in the Feb. 2 print edition of Albuquerque Business First. The startups will also be featured individually on the New Mexico Inno site in the coming days.


Effectively delivering different types of drugs is a critical part of treating various diseases and infections. Mercury Bio, a Santa Fe-based startup that emerged from stealth in August 2023, has developed a drug delivery platform it thinks can make a big splash for pharmaceutical and biotech companies.

The biomolecular drug delivery platform Mercury Bio calls its "yEV" — which stands for "chimeric extracellular vesicles" — involves drug encapsulation in natural nanoparticles and cell-specific targeting.

The startup first presented that biotechnology at the mRNA-Based Therapeutics Summit in Boston in August 2023, Mercury Bio's co-founder and CEO Bruce McCormick, Ph.D., said. McCormick is joined on Mercury Bio's leadership team by Richard Sayre, Ph.D., who serves as chief science officer, Paul Laur, chief operating officer, John Tomes, director of finance, and David Kerr, patent counsel.

Mercury Bio plans to work with biotech and pharma companies developing new drugs to integrate Mercury Bio's drug delivery platform into their methodology for getting new drugs to targets, McCormick said. It already has one such commercial deal in progress.

Six to eight more collaborating partners could work with the startup before the end of the year. McCormick said Mercury Bio is currently in negotiations with seven parties.

Besides more collaborating partners, McCormick said Mercury Bio has a few studies underway that he said the startup expects to be "quite significant."

"They'll demonstrate the enormous potential of our technology for human application," McCormick said of the studies.

One such study, which Mercury Bio is completing at the University of New Mexico, is set to be performed in March with data available in April. McCormick said a "substantial announcement" could come alongside the completion of that study.

The startup employs 16 people in Santa Fe and has four outside board members.

It operates out of the Santa Fe Business Incubator, where it maintains seven labs. It's raised around $4.5 million to date, including a $2 million seed round announced in September 2023.

In terms of future fundraising, McCormick said Mercury Bio expects to raise around $20 million in 2024. That money, he said, will fuel the startup's relocation into a standalone facility and further scientific growth.


Keep Digging

Fundings
Awards
Awards
Awards
Awards


SpotlightMore

This is what Descartes Labs' GeoVisual Search looks like on a mobile device. Shown is a search of Trump International Golf Club.
See More
Aqua Membranes CEO Craig Beckman
See More
Image via Getty
See More
Via American Inno
See More

Upcoming Events More

Sep
19
TBJ
Sep
26
TBJ

Want to stay ahead of who & what is next? Sent weekly, the Beat is your definitive look at New Mexico’s innovation economy, offering news, analysis & more on the people, companies & ideas driving your city forward. Follow The Beat

Sign Up
)
Presented By